Research Compendium/NMN
Anti-Ageing & LongevityResearch OnlyNot For Human Consumption

NMN

Nicotinamide Mononucleotide · NAD⁺ precursor

Direct NAD⁺ precursor with clinical trial support for metabolic and longevity applications - the oral alternative to injectable NAD⁺.

MECHANISM OF ACTION

NMN (nicotinamide mononucleotide) is a direct precursor to NAD⁺, synthesised endogenously from nicotinamide via the NAMPT enzyme, or from NR (nicotinamide riboside) via NRK kinase. Administered NMN is converted to NAD⁺ intracellularly and in circulation, repletion intracellular NAD⁺ stores with consequent sirtuin activation, PARP activity, and mitochondrial biogenesis. Injectable NMN delivers faster tissue repletion than oral formulations. Clinical studies in humans have demonstrated measurable NAD⁺ elevation, improved muscle insulin sensitivity, and aerobic capacity markers.

RESEARCH APPLICATIONS

  • NAD⁺ repletion - oral and injectable formats
  • Skeletal muscle insulin sensitivity (Washington University clinical data)
  • Aerobic capacity and exercise performance
  • Anti-ageing sirtuin activation
  • Combination with NR, resveratrol, or direct NAD⁺ for longevity stacks

RESEARCH HIGHLIGHTS

Human Clinical Trial: Muscle Insulin Sensitivity

2021

RCT (n=25) showed 10-week oral NMN improved skeletal muscle insulin sensitivity and improved glucose uptake vs. placebo in postmenopausal women with overweight.

Ref: Yoshino et al., Science

NAD⁺ Elevation Confirmed in Humans

2020

Single-dose NMN (100/250/500mg oral) produced dose-dependent blood NAD⁺ elevation within 2–3 hours in healthy volunteers, with 500mg producing ~2× baseline.

Ref: Irie et al., NPJ Aging

RESEARCH PROTOCOL NOTES

Common research doses250–1000 mg oral daily; injectable formats: 500–1500mg per administration
Injectable advantageBypasses oral absorption variability; faster tissue NAD⁺ repletion
Available formatsPen (1500mg - Peptide Pen NMN Pen)

Chemical Identity

Molecular FormulaC11H15N2O8P
Molecular Weight334.2 g/mol
CAS Number1094-61-7

Storage & Stability

Powder/lyophilised: cool, dry, dark environment. Sensitive to oxidation and humidity. Injectable: 2–8°C, protect from light. Less stable than NAD⁺ direct in solution.

Regulatory Status

Sold as supplement in most countries. Injectable/pharmaceutical-grade = research compound. Not WADA prohibited. SA: supplement market unregulated; injectable format = research compound.

Back to Research CompendiumView Research Compounds →